Jeito aims to back European clinical-stage companies developing breakthrough therapies for severe diseases, aiming to accelerate development and market access.

The broader financing environment shows continued fundraising activity in Europe and the U.S., with biotech venture funding in early 2026 down year-over-year, though deal values have remained around the mid-$80s millions.

Since inception, Jeito has tripled assets under management to about €1.6 billion, targeting meaningful patient-centered breakthroughs across cancer, obesity, neurology, autoimmune diseases, reproductive medicine, and cardiovascular conditions.

The press release and coverage are anchored to April 8, 2026, marking the closing date of Jeito II and related statements.

Jeito Capital, a Paris-based biopharma-focused fund, closed Jeito II at a record €1.2 billion, the largest ever raised for an independent European biopharma fund, with plans to back about 15 to 20 clinical-stage drugmakers.

Jeito II will invest up to €150 million per portfolio company, targeting 15–20 clinical-stage assets and building on the firm’s earlier €534 million fund launched in 2020.

The timing reflects industry pressures as blockbuster patents expire and pharmaceutical revenues face pressure, prompting heightened focus on clinical-stage assets with potential for major partnerships or buyouts.

The fundraise sits within a broader European fundraising wave among peers, illustrating a market dynamic that includes Sofinnova Partners, Medicxi, Frazier Life Sciences, and Atlas Venture.

The firm plans to maintain a hands-on, capital-intensive model to accelerate clinical development and strengthen Europe’s biopharma ecosystem and leadership in therapeutic innovation.

Jeito notes notable exits from its portfolio, including EyeBio’s sale to Merck for up to $1.3 billion and a Biogen-backed exit for Hi-Bio at roughly $1.15 billion in 2024, underscoring the potential value of its investments.

Europe faces challenges in scaling life sciences innovation, prompting calls for more funding and highlighting large funds and collaborations among players like Novo Holdings, Sofinnova Partners, and Medicxi.

Jeito differentiates itself with active operational support, leveraging its team’s expertise in drug development, regulatory pathways, manufacturing, and distribution to advance portfolio candidates through trials.